Clinical Trial Update: Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose [Phase 3]

View source ↗

Summary

Phase 3 trial update on immunological persistence after priming with GSK1024850A vaccine and safety/immunogenicity after booster dose; results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Streptococcal Infections

Drugs mentioned

• GSK1024850A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Streptococcal | Phase 3 | Status: COMPLETED | Results posted: 2012-03-22